软腭鳞状细胞癌的放射治疗
本文报告单中心1963至2016年治愈性收治的159例软腭鳞状细胞癌患者的放疗经验,采用单纯放疗或联合辅助化疗和/或对残留病灶行颈清扫。中位随访4年,T1至T4的5年局部控制率分别为90%、90%、70%和59%,I–III期患者5年病因特异性生存率约86%–88%,IVA/B期约58%。
要点
- I–III期软腭鳞癌根治性放疗治愈可能性较高
- IVA/B期治愈率较低但5年病因特异性生存率超过50%
- 8%患者出现放疗相关严重并发症
核心结论
- 根治性放疗对I–III期软腭鳞状细胞癌患者的治愈可能性相对较高。
- IVA/B期患者治愈率较低,但5年病因特异性生存率超过50%。
研究设计与样本
- 单中心回顾性分析,纳入1963年至2016年间治愈性治疗的159例软腭鳞状细胞癌患者。
- 治疗方式为单纯放疗或联合辅助化疗和/或对残留病灶行颈清扫,中位随访4年。
主要发现
- 5年局部控制率:T1为90%,T2为90%,T3为70%,T4为59%。
- 5年病因特异性生存率:I、II、III期分别为88%、86%、88%,IVA/B期为58%。
- 5年总生存率:I、II、III期分别为50%、57%、54%,IVA/B期为26%。
临床怎么用
- 可将根治性放疗作为I–III期软腭鳞状细胞癌的治疗选择。
- 对IVA/B期患者应告知治愈率较低但5年病因特异性生存率仍可超过50%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To report our institution's experience treating soft palate squamous cell carcinoma with radiotherapy alone or combined with adjuvant chemotherapy and/or neck dissection for residual disease. METHODS: We analyzed 159 patients treated curatively between 1963 and 2016. Median follow-up was 4 years. RESULTS: The 5-year local control rates were T1, 90%; T2, 90%; T3, 70%; and T4, 59%. The 5-year cause-specific survival (CSS) rate was nearly identical for patients with stage I-III disease (88%, 86%, and 88%, respectively) compared to stage IVA/B (58%). Five-year overall survival was similar between patients with stage I-III disease (50%, 57%, and 54%, respectively) and approximately double that of patients with stage IVA/B disease (26%). Thirteen patients (8%) had severe complications related to radiotherapy. CONCLUSIONS: The likelihood of cure after definitive radiotherapy is relatively high in patients with stage I-III disease with soft palate carcinoma. Patients with stage IVA/B disease have a lower cure rate but with a 5-year CSS exceeding 50%.
引用
- Rapp CT, Chera BS, Morris CG, et al. Radiation treatment of soft palate squamous cell carcinoma. Head Neck. 2019. PMID: 31773865. doi:10.1002/hed.26035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。